CAR T-cell Therapy Shows Promise in Treating B-cell Lymphoma

Aggressive B-cell Lymphoma

CAR T-cell therapy, specifically axicabtagene ciloleucel (axi-cel), has shown remarkable efficacy in treating aggressive B-cell lymphoma. The ZUMA-1 study, a phase 2 trial, demonstrated an overall response rate (ORR) of 82% and a complete response (CR) rate of 54% in patients with refractory or relapsed (R/R) disease. With a median follow-up of 15 months, 42% of patients maintained an objective response, and the overall survival (OS) at 18 months was 52%. Adverse events included neutropenia, anemia, and thrombocytopenia, with grade 3 or higher cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) occurring in 13% and 28% of patients, respectively.

Real-world studies have corroborated these findings, showing similar efficacy and safety profiles. For instance, a study led by Jacobson observed a best ORR of 70% and a CR rate of 50% among 122 patients treated with axi-cel. Another study by Nastoupil reported an ORR of 82% and a CR rate of 64% in 275 patients, with grade ≥ 3 CRS and ICANS occurring in 7% and 31% of patients, respectively.

Long-term follow-up studies have also shed light on the durability of responses and the importance of prophylactic anti-microbials and long-term immune surveillance post-therapy.

Tisagenlecleucel and Lisocabtagene Maraleucel

Tisagenlecleucel (tisa-cel) has been evaluated in the JULIET study, showing an ORR of 52% and a CR rate of 40% in adults with R/R diffuse large B-cell lymphoma (DLBCL). The TRANSCEND-NHL 001 study assessed lisocabtagene maraleucel (liso-cel) across various B-cell lymphomas, reporting an ORR of 73% and a CR rate of 53%. Both therapies have demonstrated manageable safety profiles, with improvements in health-related quality of life (HRQoL) observed in responders.

Special Considerations and Future Directions

Pretreatment comorbidities and bridging therapy have been identified as factors influencing outcomes. The impact of bridging therapy on progression-free survival (PFS) and OS remains under investigation, with prospective studies needed to define optimal strategies.

Despite the exclusion of patients with central nervous system (CNS) involvement in pivotal trials, anecdotal reports suggest potential benefits of CAR T-cell therapy in this population, warranting further study.

Overall, CAR T-cell therapy represents a significant advancement in the treatment of R/R aggressive B-cell lymphoma, with ongoing research aimed at optimizing its use and exploring its application in other B-cell lymphoma subtypes.